AP‑4 predicts poor prognosis in non‑small cell lung cancer

Gong,Hai; Han,Shaorong; Yao,Hui; Zhao,Hui; Wang,Yanming

doi:10.3892/mmr.2014.2209

July-2014 Volume 10 Issue 1

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

July-2014 Volume 10 Issue 1

Full Size Image

Article

AP‑4 predicts poor prognosis in non‑small cell lung cancer

Authors:
- Hai Gong
- Shaorong Han
- Hui Yao
- Hui Zhao
- Yanming Wang
View Affiliations / Copyright

Affiliations: Department of Radiation Oncology, Jinan Military General Hospital, Jinan, Shandong 250031, P.R. China
Pages: 336-340
|
Published online on: May 2, 2014

https://doi.org/10.3892/mmr.2014.2209
Expand metrics +

Abstract

The basic helix‑loop‑helix transcription factor activating enhancer‑binding protein (AP)‑4 has been found to be involved in tumor biology. However, the role of AP‑4 in non‑small cell lung cancer (NSCLC) has yet to be elucidated. The present study aimed to investigate the role of AP‑4 expression in NSCLC. AP‑4 expression as analyzed using quantitative polymerase chain reaction and western blot analyses of 42 fresh NSCLC samples and matched adjacent noncancerous tissues. Immunohistochemistry was performed to assess the clinical significance of AP‑4 expression in tumor tissues of NSCLC patients (n=240) and matched adjacent noncancerous tissues. The correlation between AP‑4 expression, clinicopathological features and clinical outcome were investigated. AP‑4 expression was found to be increased in the NSCLC samples at the gene and protein levels compared with the matched adjacent noncancerous tissues. Immunohistochemistry revealed that the positive expression rates of AP‑4 in the 240 NSCLC samples and the matched adjacent noncancerous tissues were 48.3 and 5.8%, respectively. Positive AP‑4 expression was found to be significantly associated with the tumor, nodes and metastasis stage and nodal status. Furthermore, patients with NSCLC tumors expressing AP‑4 were observed to have a poorer prognosis than those without AP‑4 expression. Multivariate analysis revealed that AP‑4 expression was an independent prognostic marker (hazard ratio, 2.543; 95% confidence interval, 1.18‑5.016; P=0.016) in NSCLC. Thus, positive AP‑4 expression may be a potential prognostic marker for NSCLC.

View Figures

View References

1	Chen YT, Feng B and Chen LB: Update of research on drug resistance in small cell lung cancer chemotherapy. Asian Pac J Cancer Prev. 13:3577–3581. 2012. View Article : Google Scholar : PubMed/NCBI
2	Fossella F, Pereira JR, von Pawel J, Pluzanska A, Gorbounova V, Kaukel E, Mattson KV, Ramlau R, Szczesna A, Fidias P, Millward M and Belani CP: Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol. 21:3016–3024. 2003. View Article : Google Scholar : PubMed/NCBI
3	Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar
4	Jones S: An overview of the basic helix-loop-helix proteins. Genome Biol. 5:2262004. View Article : Google Scholar : PubMed/NCBI
5	Lee SU, Song HO, Lee W, Singaravelu G, Yu JR and Park WY: Identification and characterization of a putative basic helix-loop-helix (bHLH) transcription factor interacting with calcineurin in C. elegans. Mol Cells. 28:425–461. 2009.PubMed/NCBI
6	Jackstadt R, Röh S, Neumann J, Jung P, Hoffmann R, Horst D, Berens C, Bornkamm GW, Kirchner T, Menssen A and Hermeking H: AP4 is a mediator of epithelial-mesenchymal transition and metastasis in colorectal cancer. J Exp Med. 210:1331–1350. 2013. View Article : Google Scholar : PubMed/NCBI
7	Hu BS, Zhao G, Yu HF, Chen K, Dong JH and Tan JW: High expression of AP-4 predicts poor prognosis for hepatocellular carcinoma after curative hepatectomy. Tumour Biol. 34:271–276. 2013. View Article : Google Scholar : PubMed/NCBI
8	Reck M, Heigener DF, Mok T, Soria JC and Rabe KF: Management of non-small-cell lung cancer: recent developments. Lancet. 382:709–719. 2013. View Article : Google Scholar : PubMed/NCBI
9	Cao J, Tang M, Li WL, Xie J, Du H, Tang WB, Wang H, Chen XW, Xiao H and Li Y: Upregulation of activator protein-4 in human colorectal cancer with metastasis. Int J Surg Pathol. 17:16–21. 2009. View Article : Google Scholar : PubMed/NCBI
10	Xinghua L, Bo Z, Yan G, Lei W, Changyao W, Qi L, Lin Y, Kaixiong T, Guobin W and Jianying C: The overexpression of AP-4 as a prognostic indicator for gastric carcinoma. Med Oncol. 29:871–877. 2012. View Article : Google Scholar : PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

AP‑4 predicts poor prognosis in non‑small cell lung cancer

This article is mentioned in:

Abstract

Figure 1

Figure 2

Figure 3

Figure 4

Related Articles